Search filters

List of works by Riikka Räty

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

scientific article published on 5 July 2016

A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients

scientific article

Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study

scientific article

Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3

scientific article published on 21 December 2020

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial ⬇️

scientific article published on August 28, 2013

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

scientific article published on 29 January 2018

Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk

scientific article published on 07 December 2020

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma

scientific article published on 24 May 2018

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

scientific article published on 27 June 2016

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

scientific article published on August 2009

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

scientific article published on 27 December 2016

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

scientific article published on 29 May 2012

Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

scientific article

Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data

scientific article

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

scientific article

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

scientific article published on 17 August 2017

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

scientific article published on 23 December 2009

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

scientific article

p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma

scientific article published on 04 August 2020

Paulina is supported by:

About Paulina

Help